このエントリーをはてなブックマークに追加
ID 18181
Eprint ID
18181
フルテキストURL
Thumnail 80_1105.pdf 4.8 MB
タイトル(別表記)
Studies on (90)YCl(3) Colloid for Clinical Use Part 2. Experimental and Clinical Use by Intraperitoneal and Intralymphatic Administration of (90)YCl(3) Colloid
著者
立花 明久 岡山大学医学部第1外科教室
抄録
It is an expectation on radiocolloid therapy from the standpoint of prevention of side efects, that the administered radiocolloid is not removing in blood stream or in some organs. Old (90)YCl(3) colloid at pH 7.0 (20mμ diameter) and new type of a mixture of YCl(3) and (90)YCl(3) colloid at pH 7.0 (3-15μ diameter) were administered into peritoneal cavity of mice and rabbits. The distributions of administered (90)Y in serum and organs were compared. Also, these two colloids were examined by intralymphatic administration for clinical use, and the distributions were observed in serum and the excretion of urine. 1) (90)Y in peripheral blood by peritoneal administration of mice were higher in old(90)YCl(3) colloid than that of new type of YCl(3) and (90)YCl(3) mixture. The c. p. m. in peripheral blood were generally decreased by addition of YCl(3). Minimum distribution in peripheral blood was obtained by addition of 1mg/ml of YCl(3). 2) The same results were obtained from rabbit experiment. Old (90)YCl(3) colloid was 2 times of c. p. m. than that of new type mixture colloid at 7th day. (90)Y excretion in urine of old (90)Y colloid was 51 times than that of new type colloid after 3 hrs colloid administration. The distributions of old (90)YCl(3) colloid were spleen, kidney, liver, marrow, lung, heart muscle, and thigh, in the orders, 7 days after administration, and that of new type colloid were spleen, liver, marrow, lung, kidney, heart muscle, and thigh. (90)Yc. p. m. of old colloid was 4 times than that of new colloid in kidney, heart muscle and thigh. New colloid was 5 times than old colloid in spleen, liver, marrow and lung. 3) (90)Yc. p. m. in peripheral blood of intralymphatic administration was observed in both colloid, below 1% excretion in urine of administered dose after 3 days. In clinical use, one case was visible reduction of metastatic lymphnode, but clinical effects were not clear, for control patients were end stadium of malignant tumor.
発行日
1968-12-30
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
80巻
11-12号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
1105
終了ページ
1117
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/80/11-12/80_11-12_1105/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/
言語
Japanese
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Eprints Journal Name
joma